drugset / Trial / NCT03740217
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
Phase 1
Completed
15 enrolled
Calliditas Therapeutics AB
Eurofins Optimed · collabYork Bioanalytical Solution · collab
RandomizedCrossoverOpen-labelOther
Summary
The study will be a comparative oral bioavailability study between GKT137831 capsules and tablets, together with an assessment of the impact of concomitant food intake on the relative bioavailability of GKT137831 tablets. This will be a randomized three-way open cross-over study.
Timeline
- Start
- 2018-12-19
- Primary completion
- 2019-02-06
- Completion
- 2019-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Setanaxib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.